Retatrutide Dosage and Protocols
Retatrutide dosage protocols reported in published research, plus reconstitution and storage.
Research Protocol Doses Reported in Published Literature
Research Disclaimer: Doses reported below are from published preclinical research protocols. Retatrutide (Triple Agonist) is not approved for human use by the FDA or any regulatory agency. This information is provided for research reference only and does not constitute a dosing recommendation. All doses above are reported from published research protocols using laboratory subjects. Refer to the cited studies in the Research Studies section above for original source data.
Reported protocol doses
Reconstitution
A 10mg vial with 2mL of bacteriostatic water is the pairing reported most often. 10mg vial + 2mL bacteriostatic water = 5mg/mL. Start low (1–2mg / 20–40 units) weekly and titrate up no faster than every 4 weeks.
Work out your own concentration with the reconstitution calculator.
Doses shown are those reported in published research, not a recommendation.
References
- Triple–Hormone–Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial
- Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. N Engl J Med. 2023;389:514-526.
- Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.
- Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study
- Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544.
- Effects of retatrutide on body composition in people with type 2 diabetes. Lancet Diabetes Endocrinol. 2025.